# **Charity Registration Number: 1148145 Company Registration Number: 06672185 (England and Wales)**
# **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2022**
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **CONTENTS**
||**Page**|
|---|---|
|Legal and administrative information|2|
|Trustees’ Report|3 to 7|
|Independent examiners report|8|
|Statement of financial activities|9|
|Balance sheet|10|
|Notes to the financial statements|11 to 17|
1
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **LEGAL AND ADMINSTRATIVE INFORMATION**
## **Trustees**
Prof J Newell-Price - resigned 01/12/2021 Prof M Pritchard - appointed 01/12/2021 Prof J Ramage - retired 06/12/2021 Prof T H Shah Prof C Thirlwell
## **Registered Office**
First Floor Livery Place 35 Livery Street Birmingham B3 2PB
**Charity number:** 1148145
**Company number:** 06672185 (registered in England and Wales)
## **Independent Examiner**
Jasbir Rai BVSC Accountancy Services First Floor Livery Place 35 Livery Street Birmingham B3 2PB
2
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022**
The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2022.
## **Trustees**
The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:
Prof J Newell-Price - resigned 01/12/2021
Prof M Pritchard - appointed 01/12/2021
Prof J Ramage - retired 06/12/2021
Prof T H Shah
Prof C Thirlwell
None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.
The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.
## **Governing document**
The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.
## **Organisational structure**
The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.
The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.
## **Risk management**
The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.
3
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022**
## **Objectives and activities**
The charity’s objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.
In furtherance of its objects, the Society shall have the following powers:
1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.
The summary of main activities in relation to the charity objectives are as follows:
- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement
## **Achievements and performance**
## **UKI NETS 19[th] Annual Conference: Online 2021**
The 19th Annual Conference of the Society was held Online on Monday 6 to Tuesday 7 December 2021. This was the second time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 182 people to the event. Content was provided on-demand to delegates following the conference.
Sessions ran from morning until early afternoon both days. The programme contained sessions focused on: challenges in clinical practice; clinical trials overview; a debate regarding the use of PRRT for pancreatic NETs; the national pilot of liver transplantation in NETs; a challenging the experts live NET MDT session; NET translational medicine. Oral abstract presentations included topics such as Incidence, prevalence of survival of neuroendocrine neoplasia in England, Tracking circulating cell free tumour derived DNA in patients with neuroendocrine neoplasms and an update on the effects of debulking surgery and liver directed intra-arterial therapies on quality of life in patients with metastatic neuroendocrine tumours. The conference ended with a Prize Giving session. Satellite symposia were also held by sponsors.
4
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022**
## **Provision of travel grants**
As the conference was held online in 2021, no travel grants were awarded.
## **Provision of meeting awards**
Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 19[th] Annual Conference.
## **Provision of Research grants**
UKI NETS and the NET Patient Foundation awarded one research grant of £30k to provide pumppriming funds to support a research project aimed at improving outcomes for patients with Neuroendocrine Tumours.
## **Public Engagement**
UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with Neuroendocrine Cancer UK and other organisations.
## **Educational activities**
NETs for Newcomers:
On 12th May 2022 UKINETS presented the fifth annual one day course for doctors of all specialties who wished to learn more about Neuroendocrine Tumours. It was held virtually for the second time due to the ongoing Covid-19 pandemic. The course was delivered by an expert multidisciplinary faculty and included ‘mock MDT’ practice in small groups. Approximately 47 HCPs attended and feedback was very positive.
International Symposium on Carcinoid Heart Disease:
The Second International Symposium on Carcinoid Heart Disease was held in Birmingham on 2 September 2021 in collaboration with other organisations. Sessions covered: Aetiology and quantifying impact; Current Management of CHD; Surgical Management of CHD and Peri-operative Management and Future Care.
## **Dietitians’ Working Group**
The chair of the dietitians’ working group remained as a co-optee on the Executive Committee. The group worked on a survey, audit and nutrition guideline.
## **Sponsor Support**
There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.
5
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022**
## **Website**
The charity’s website provides an important tool to inform members and the general public about the activities of the Society. http://www.ukinets.org.
## **Communications**
UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS.
## **Liver transplantation delivery programme**
The development of a liver transplantation delivery programme and associated service development and research opportunities was delivered by UKI NETS in collaboration with LAG, NHFBT and SIGTO.
## **Clinical Trials**
The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETS Annual Conference. The Research SubCommittee of UKINETS also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting.
## **Link with the European Neuroendocrine Tumour Society (ENETS)**
UKI NETS continues to provide inclusive membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the journal _Neuroendocrinology_ and a reduced rate for the ENETS annual conference _._ This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.
## **Financial review**
## **Principal funding sources**
Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.
6
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2022**
## **Reserves policy**
The reserve policy takes into consideration the major risks that could face the Society.
It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of two years’ expenditure. The balance sheet indicates that there are £135831 unrestricted funds as at 31 August 2022. This provides sufficient funds to cover management, administration and support costs.
## **Plans for future periods**
The UKI NETS 20th Annual Conference is scheduled to be held face-to-face in December 2022 following two years of virtual meetings due to the coronavirus pandemic.
Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference. Content will be available on-demand following the conference.
Other plans for the coming year include:
- Holding a further NETs for Newcomers training event in-person in May 2023.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs.
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members
Working with other societies and foundations to fund and promote NETS knowledge and research
The Trustees Report was approved by the Board of Trustees and signed on its behalf by:
Dr T H Shah
Trustee Dated: 30/04/2023
7
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **INDEPENDENT EXAMINERS REPORT**
## **TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2022.J
## **Responsibilities and basis of report**
As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).
Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity’s financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011Act.
## **Independent Examiner’s Statement**
I have completed mu examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.
Jasbir Rai ACMA BVSC Accountancy Services First Floor Livery Place 35 Livery Street Birmingham B3 2PB
Dated: 20/04/23
8
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 AUGUST 2022**
|**Note**
**Income from;**
Donations and legacies
3
Charitable activities
Sponsorship
4
Grants
4
**Total income**
**Expenditure on;**
Charitable activities
Research grant
Other charitable expenditure
5
**Total charitable expenditure**
Other resources expended
**Total resources expended**
**Net income for the year/Net movement in funds**
**Fund balances at 1 September 2021**
**Fund balances at 31 August 2022**|**Unrestricted**
**funds**
**2022**
**£**
20,108
77,784
-
97,892
-
86,061
86,061
37
86,097
11,795
124,035
135,830|**Restricted**
**funds**
**2022**
**£**
-
-
-
-
-
-
-
-
-
-
23,525
23,525|**Total**
**2022**
**£**
20,108
77,784
-
97,892
-
86,061
86,061
37
86,097
11,795
147,560
159,355|**Total**
**2021**
**£**
17,121
78,045
-
|
|---|---|---|---|---|
|||||95,166|
|||||-
85,705
|
|||||85,705|
|||||95
|
|||||85,800|
|||||9,366
147,560
|
|||||147,560|
The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.
9
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **BALANCE SHEET AS AT 31 AUGUST 2022**
|**Notes**
**Fixed Assets**
**Tangible Assets**
**3**
**Current Assets**
Cash at Bank
Debtors
**4**
**Creditors**
Amounts falling due within one year
**5**
**Net Current Assets**
**Total Current Assets less Current**
**Liabilities**
**Capital and Reserves**
Restricted funds
**6**
Unrestricted funds
**6**|**2022**
**£**
**0**
**115,983**
**49,918**
**165,901**
**6,546**
**159,355**
**159,355**
**23,525**
**135,830**
**159,355**|**2021**
**£**
**0**
**98,765**
**64,327**|
|---|---|---|
|||**163,092**
**15,532**|
|||**147,560**|
|||**147,560**|
|||**23,525**
**124,035**|
|||**147,560**|
For the year ending 31 August 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2022 in accordance with section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees on 30/04/2023, and signed on behalf of the board by:
Prof T H Shah -Trustee
10
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **1. Accounting Policies**
## **Accounting convention**
The accounts have been prepared in accordance with the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a “Public Benefit Entity as defined by FRS 102.
The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.
The financial statements are prepared in sterling, which is the functional currency of the charity.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
## **Going concern**
At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis if accounting in preparing the financial statements.
## **Charitable funds**
Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
## **Incoming resources**
These are included in the Statement of Financial Activities (SOFA) when:
- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.
Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.
Charitable income includes sponsorship of the annual conference and contributions towards the charity’s objectives.
11
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **1. Accounting Policies (continued)**
## **Resources expended**
Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.
Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.
Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.
## **Incoming resources with related expenditure**
When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.
## **Tangible fixed assets**
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:
Computers – straight line over 3 years
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.
## **Cash and cash equivalents**
Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
## **Financial instruments**
The charity has elected to apply the provisions of Section 11 “Basic Financial Instruments” and Section 12 “Other Financial Issues” of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.
12
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **1. Accounting Policies (continued)**
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.
## _**Basic financial assets**_
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.
## _**Basic financial liabilities**_
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
## _**De-recognition of financial liabilities**_
Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.
## **2. Critical accounting estimates and judgements**
In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
## **3. Donations and legacies**
|Donations and gifts
Membership fees
Total for the year|**Unrestricted**
**Funds**
**2022**
**£**
-
20,108
20,108|**Restricted**
**funds**
**2022**
**£**
-
-
-|**Total**
**2022**
**£**
-
20,108
20,108|**Total**
**2021**
**£**
-
17,121|
|---|---|---|---|---|
|||||17,121|
13
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **4. Charitable activities**
|Sales within charitable activities
Performance related grants
Total for the year
**Analysis by fund**
Unrestricted funds
Restricted funds
**Charitable activities**
Depreciation and impairment
Conferences and newsletters
Share of support costs (note 6)
Share of governance costs (note 6)
Application developments costs
**Analysis by fund**
Unrestricted funds
Restricted funds|**Sponsorship**
**2022**
**£**
77,748
-
77,748
-
|**Grants**
**2022**
**£**
-
-
-
-||**Total**
**2022**
**£**
77,748
-
77,748
-
**2022**
**£**
-
31,919
31,919
23,876
30,266
-
86,061
86,061
-
86,601|**Total**
**2021**
**£**
78,045
-|
|---|---|---|---|---|---|
||||||78,045|
||||||-
-|
||||||-|
||||||**2021**
**£**
-
20,484|
||||||20,484
29,818
24,603
10,800|
||||||85,705|
||||||74,905
10,800|
||||||85,705|
## **5. Charitable activities**
14
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **6. Support costs**
|ENET membership subscriptions
Website
Management fees
Independent examiner and
accountancy fees
Other operating costs
Committee meetings
Analysed between
Charitable activities|**Support**
**costs**
**2022**
**£**
6,380
3,946
13,550
-
-
-
23,876
23,876|**Governance**
**costs**
**2022**
**£**
-
-
-
1,680
27,596
990
30,266
30,266|**Total**
**2022**
**£**
6,380
3,946
13,550
1,680
27,596
990
54,142
54,142|**Total**
**2021**
**£**
12,178
3,090
14,550
1,440
18,620
4,543|
|---|---|---|---|---|
|||||54,421|
|||||54,421|
## **7. Trustees**
None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2022 - £nil).
## **8. Employees**
There were no employees during the year. (2022 – nil).
## **9. Tangible fixed assets**
**Computers £ Cost** - At 1 September 2021 and 31 August 2022 **Depreciation and impairment** - At 1 September 2021 and 31 August 2022 **Carrying amount** - At 31 August 2022 At 31 August 2021 Charitable activities -
15
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **10. Financial instruments**
|**Carrying amount of financial assets**
Debt instruments measured at amortised cost
**Carrying value of financial liabilities**
Measured on amortised costs
**1. Debtors**
**2022**
**£**
Amount due from Bio
36,318
Prepayments
13,600
49,918|**2022**
**2021**
**£**
**£**
-
-
-
-
**2021**
**£**
50728
13,599
64,327|
|---|---|
## **11. Debtors**
## **12. Creditors: amounts falling due within one year**
|Deferred income
Other creditors
Accruals and deferred
income
**3. Other deferred income**
Other deferred income|**2022**
**£**
0
2,840
3,706
6,546|**2021**
**£**
4,732
0
10,800
15,532
**2022**
**2021**
**£**
**£**
-
4,732|
|---|---|---|
## **13. Other deferred income**
16
**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**
## **NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022**
## **14. Restricted funds**
The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:
|Grants
TransNET
Mobile app development|**Balance at 1**
**September**
**2021**
**£**
11,150
4,925
7,450
23,525|**Movement**
**in funds**
**Incoming**
**resources**
**£**
-
-
-
-|**Resources**
**expended**
**£**
-
-
-
-|**Balance**
**at 31**
**August**
**2022**
**£**
11,150
4,925
7,450|
|---|---|---|---|---|
|||||23,525|
## **15. Analysis of net assets between funds**
Fund balances at 31 August 2022 and 31 August 2021 are represented by current assets/(liabilities.
## **16. Related party transaction**
There were no disclosable related party transactions during the year (2022 – none).
17